nach oben

Erschienen in:

01.11.2012 | Original Article

A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer

verfasst von: Hyun-Jeong Shim, Dae-Eun Kim, Jun-Eul Hwang, Woo-Kyun Bae, Taek-Keun Nam, Kook-Joo Na, Sang-Hee Cho, Ik-Joo Chung

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Concurrent chemoradiotherapy (CRT) is a main treatment option for patients with advanced oesophageal cancer. However, improvement of survival outcomes and toxicities according to the selected treatment is still needed. This phase II trial was conducted to assess the efficacy and safety of concurrent CRT with weekly docetaxel and cisplatin in advanced oesophageal cancer.

Methods

Patients with unresectable oesophageal cancer due to advanced stage or patients medically unfit for surgery were enrolled. Patients received 20 mg/m² docetaxel and 25 mg/m² cisplatin in weeks 1, 2, 3, 5, 6, and 7 with concurrent 54-Gy radiotherapy at 200 cGy/day.

Results

Thirty-six patients with oesophageal squamous cell carcinoma were enrolled from December 2007 to December 2009. Among them, the toxicity and response rate of 35 were evaluated. Thirty-five patients completed radiotherapy as planned, and 33 completed chemotherapy as planned. Grade 3 or 4 toxicity during CRT included leucopenia (5.7 %), febrile neutropenia (2.9 %), oesophagitis (22.9 %), and tracheo-oesophageal fistula (5.7 %). After CRT, 8 patients (22.9 %) had a complete response, 22 (62.9 %) had a partial response, 4 (11.4 %) had stable disease, and 1 (2.9 %) had progressive disease. Improvement of dysphagia was observed in 85.3 %. At a median follow-up of 26.7 months, the median time to progression was 13.5 months, and median overall survival was 26.9 months. The 3-year progression-free survival rate was 16.7 %, and survival rate was 27.8 %.

Conclusion

Concurrent CRT with weekly docetaxel and cisplatin was well tolerated and is a convenient combination with promising efficacy. This result indicated favourable activity in terms of both tumour and symptom control.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRef

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics. CA Cancer J Clin 59(4):225–249PubMedCrossRef

Urschel JD, Vasan H (2003) A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 185(6):538–543PubMedCrossRef

al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B (1997) Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 15(1):277–284PubMed

Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA 281(17):1623–1627PubMedCrossRef

Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, Fujita H, Takiyama W, Ohtsu T (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15(6):955–959PubMedCrossRef

Kim JY, Do YR, Park KU, Kim MK, Lee KH, Bae SH, Ryoo HM, Baek JH, Song HS (2010) A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol 66(1):31–36PubMedCrossRef

Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L (1997) Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 3(12 Pt 1):2431–2438PubMed

Pradier O, Rave-Frank M, Lehmann J, Lucke E, Boghun O, Hess CF, Schmidberger H (2001) Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki). Int J Cancer 91(6):840–845PubMedCrossRef

10.

Wilson GD, Bentzen SM, Harari PM (2006) Biologic basis for combining drugs with radiation. Semin Radiat Oncol 16(1):2–9PubMedCrossRef

11.

Schull B, Kornek GV, Schmid K, Raderer M, Hejna M, Lenauer A, Depisch D, Lang F, Scheithauer W (2003) Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancer. Oncology 65(3):211–217PubMedCrossRef

12.

Yamamoto N, Nishimura Y, Nakagawa K, Matsui K, Fukuoka M (2006) Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer. Cancer Chemother Pharmacol 58(3):285–291PubMedCrossRef

13.

Ogilvie AL, Dronfield MW, Ferguson R, Atkinson M (1982) Palliative intubation of oesophagogastric neoplasms at fibreoptic endoscopy. Gut 23(12):1060–1067PubMedCrossRef

14.

Bown SG, Hawes R, Matthewson K, Swain CP, Barr H, Boulos PB, Clark CG (1987) Endoscopic laser palliation for advanced malignant dysphagia. Gut 28(7):799–807PubMedCrossRef

15.

Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1–10PubMedCrossRef

16.

Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP (2002) INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20(5):1167–1174PubMedCrossRef

17.

Button MR, Morgan CA, Croydon ES, Roberts SA, Crosby TD (2009) Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 73(3):818–823PubMedCrossRef

18.

Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C (2003) Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer 89(4):630–633PubMedCrossRef

19.

Lorenzen S, Duyster J, Lersch C, von Delius S, Hennig M, Bredenkamp R, Peschel C, Lordick F (2005) Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer 92(12):2129–2133PubMedCrossRef

20.

Shim HJ, Cho SH, Hwang JE, Bae WK, Song SY, Cho SB, Lee WS, Joo YE, Na KJ, Chung IJ (2010) Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer. Am J Clin Oncol 33(6):624–628PubMedCrossRef

21.

Pasini F, de Manzoni G, Pedrazzani C, Grandinetti A, Durante E, Gabbani M, Tomezzoli A, Griso C, Guglielmi A, Pelosi G, Maluta S, Cetto GL, Cordiano C (2005) High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol 16(7):1133–1139PubMedCrossRef

22.

Hihara J, Yoshida K, Hamai Y, Emi M, Yamaguchi Y, Wadasaki K (2007) Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer. Anticancer Res 27(4C):2597–2603PubMed

23.

Font A, Arellano A, Fernandez-Llamazares J, Casas D, Boix J, Cardenal J, Margeli M, Manzano JL, Abad A, Rosell R (2007) Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer. Clin Transl Oncol 9(3):177–182PubMedCrossRef

24.

Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Ishiyama H, Hayakawa K (2008) A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501). Radiother Oncol 87(3):398–404PubMedCrossRef

25.

Li QQ, Liu MZ, Hu YH, Liu H, He ZY, Lin HX (2010) Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus 23(3):253–259PubMedCrossRef

26.

Day FL, Leong T, Ngan S, Thomas R, Jefford M, Zalcberg JR, Rischin D, McKendick J, Milner AD, Di Iulio J, Matera A, Michael M (2011) Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer. Br J Cancer 104(2):265–271PubMedCrossRef

27.

Ruhstaller T, Widmer L, Schuller JC, Roth A, Hess V, Mingrone W, von Moos R, Borner M, Pestalozzi BC, Balmermajno S, Koberle D, Terraciano L, Schnider A, Bodis S, Popescu R (2009) Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol 20(9):1522–1528PubMedCrossRef

28.

Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R (2008) Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26(7):1086–1092PubMedCrossRef

29.

Makino T, Doki Y (2011) Treatment of T4 esophageal cancer. Definitive chemo-radiotherapy vs chemo-radiotherapy followed by surgery. Ann Thorac Cardiovasc Surg 17(3):221–228PubMedCrossRef

30.

Ikeda E, Kojima T, Kaneko K, Minashi K, Onozawa M, Nihei K, Fuse N, Yano T, Yoshino T, Tahara M, Doi T, Ohtsu A (2011) Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. Jpn J Clin Oncol 41(8):964–972

31.

Kaneko K, Ito H, Konishi K, Kurahashi T, Ito T, Katagiri A, Yamamoto T, Kitahara T, Mizutani Y, Ohtsu A, Mitamura K (2003) Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer 88(1):18–24PubMedCrossRef

32.

Rice TW, Blackstone EH, Rusch VW (2010) 7th edition of the AJCC cancer staging manual: esophagus and esophagogastric junction. Ann Surg Oncol 17(7):1721–1724PubMedCrossRef

33.

Hsu PK, Wu YC, Chou TY, Huang CS, Hsu WH (2010) Comparison of the 6th and 7th editions of the American Joint Committee on Cancer tumor-node-metastasis staging system in patients with resected esophageal carcinoma. Ann Thorac Surg 89(4):1024–1031PubMedCrossRef

34.

Talsma K, van Hagen P, Grotenhuis BA, Steyerberg EW, Tilanus HW, van Lanschot JJ, Wijnhoven BP (2012) Comparison of the 6th and 7th editions of the UICC-AJCC TNM classification for esophageal cancer. Ann Surg Oncol 19(7):2142–2148PubMedCrossRef

Titel: A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer
verfasst von: Hyun-Jeong Shim
Dae-Eun Kim
Jun-Eul Hwang
Woo-Kyun Bae
Taek-Keun Nam
Kook-Joo Na
Sang-Hee Cho
Ik-Joo Chung
Publikationsdatum: 01.11.2012
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 5/2012
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-012-1962-3

Springer Medizin

A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer